Abstract 168P
Background
Routine genomic profiling in metastasic solid tumors has an impact on survival by selecting targeted therapies and montoring treatment response. Moreover, feasibility and efficiency of liquid biopsy (LB) in pancreatic cancer has been studied as tissue is not always available in these tumors given the frequent lack of tissue in these tumors.
Methods
We present an ambispective observational study in patients with locally advanced or metastatic pancreatic cancer who underwent LB before starting chemotherapy. The primary end point was to determine the prevalence of pathological molecular alterations in circulating tumor DNA (ctDNA) and their concordance with next generation sequencing in tumor tissue (TNGS). A secondary end point was the study of circulating tumor cells (CTCs) as a poor prognostic factor for survival.
Results
A total of 30 patients were included between May 2020 and September 2022. Women were 53.3% of them, and the median age was 65.5 years (37-85). At the time of LB, 86.7% had metastatic disease, 6.7% had stage III, and 6.7% had stage II. 83.4% were about to initiate a first-line chemotherapy. 86.7% of the patients had also undergone TNGS. In both LB and TNGS, one or more molecular alterations were found in 80% of patients. Fourteen different molecular alterations were found in LB, with the most prevalent mutations in TP53 (56.6%), KRAS (53.3%), ERBB2 (16.6%), MET (4%), and EGFR (4%). In TNGS, 12 alterations were found, with the most prevalent being TP53 (46.6%), KRAS (60%), MET (23.3%), and EGFR (13.3%). The concordance rate between BL and TNGS was > 70%. The median overall survival (OS) was 5.5 months (95%CI:3.6-7.4). In patients without CTCs, the OS was 6.3 months (95%CI:4.7-8.0), while patients with CTCs had an OS of 3.6 months (95%CI:1.6-5.6).
Conclusions
80% of patients presented molecular alterations in both LB and TNGS with a matching rate > 70%. The most prevalent mutations were TP53, KRAS, MET, EGFR and ERBBE in the two analyses. The presence of CTCs is a poor prognostic factor.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
20P - Effects of <italic>Apis dorsata</italic> honey on the expression of selected CYP450, pro-apoptotic, and anti-apoptotic genes during induced cytotoxicity in cyclophosphamide-treated human lung carcinoma (A549) cells
Presenter: Jose Kenneth Narag
Session: Cocktail & Poster Display session
Resources:
Abstract
21P - Hsa_circ_0009061 inhibits the progression of bladder cancer through the miR-889-3p/CPEB3 axis
Presenter: Minkang Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
22P - Exploring exportin-1 as a therapeutic vulnerability in lung squamous cell carcinoma
Presenter: Vidushi Durani
Session: Cocktail & Poster Display session
Resources:
Abstract
23P - Identification of HPSE as potential novel therapeutic target for lung adenocarcinoma patients
Presenter: Samuel Doré
Session: Cocktail & Poster Display session
Resources:
Abstract
24P - High-throughput plasma proteomics profiling in early breast cancer
Presenter: Isabella Lombardo
Session: Cocktail & Poster Display session
Resources:
Abstract
25P - Immunohistochemical analysis of ROR1 and BMI-1 expression in luminal breast cancer
Presenter: Sergey Vtorushin
Session: Cocktail & Poster Display session
Resources:
Abstract
26P - Associations between cancer stem cells (CSC) markers and androgen (AR) and estrogen (ER) receptors expression in prostate cancer (PCa)
Presenter: Marina Puchinskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
27P - Proteomic profiling reveals organ-specific differences in metastases and identifies potential biomarkers for recurrence risk in localized colon cancer
Presenter: Blanca García-Micó
Session: Cocktail & Poster Display session
Resources:
Abstract
28P - Collagen-activated signalling pathway is significantly hypermethylated in high-grade serous ovarian cancer (HGSOC) patients treated with platinum-containing neoadjuvant chemotherapy (NACT)
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract
29P - Quantitative tissue analysis reveal adenylate kinase 2 protein signatures: Therapeutic target for meningioma
Presenter: Rashmi Rana
Session: Cocktail & Poster Display session
Resources:
Abstract